Allogene Therapeutics Announces Expansion of Scientific Advisory Board
“We are pleased to welcome Drs. Abraham, Brenner, Forman and Lim, renowned experts in immunotherapy, oncology and pioneering leaders across cell and gene therapy and cell signaling systems, to Allogene’s
The new members of Allogene’s SAB include:
Robert Abraham, Ph.D. – Dr. Abraham is Senior Vice President and Group Head of Pfizer’s Oncology Research & Development Group. He also serves as the Director of the Pfizer Postdoctoral program, helping develop talented early career scientists into outstanding industry and academic researchers. Author of more than 200 scientific publications, Dr. Abraham has served on and chaired grant review panels at the National Institutes of Health, and is a reviewer for leading scientific journals, including Nature, Science, and Cell. Dr. Abraham served as Director, Professor, and consultant at the Mayo Clinicand Mayo Foundation; as Duke University'sGlaxo-Wellcome Professor of Molecular Cancer Biology; and as Professor and Director of The Burnham Institute'sCancer Center in La Jolla, California. Dr. Abraham holds a Ph.D. in pharmacology from the University of Pittsburghand a B.S. in Biology from Bucknell University. Dr. Abraham previously served as a member of Allogene’s Board of Directors.
Malcolm K. Brenner, M.D., Ph.D. – Dr. Brenner is the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicineand founding Director of the Center for Cell and Gene Therapyat the Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist Hospital. As a professor at the Baylor College of Medicine, Dr. Brenner’s expertise spans cell and gene therapy, molecular and human genetics, pediatrics, and translational biology & molecular medicine. His primary research interest is the use of gene transfer to augment the immune response to human tumors, using vaccines and adoptive transfer of genetically modified T cells. Dr. Brenner is also member of the National Academy of Medicine. Dr. Brenner holds a Ph.D. from the University of Cambridge, a M.B.Ch.B. from Westminster Medical College, and a B.S. from the University of Cambridge. Stephen J. Forman, M.D. – Dr. Forman is the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and leader of the Hematologic Malignancies and Stem Cell Transplantation Instituteand Director of the T Cell Therapeutics Research Laboratoryat the City of Hope Comprehensive Cancer Center. An expert in leukemia, lymphoma and bone marrow transplantation, Dr. Forman has served at City of Hope for more than 40 years, deeply involved with the translational and clinical research at City of Hope's Toni Stephenson Lymphoma Center, Center for CAR T Cell Therapy, Judy and Bernard Briskin Center for Multiple Myeloma Researchand the Gehr Family Center for Leukemia Research. Dr. Forman was recognized by the American Society for Blood and Marrow Transplantationas the 2019 E. Donnall Thomas Lecturer, and awarded the 2019 DKMS Mechtild Harf Science Award. Dr. Forman holds an M.D. from the University of Southern Californiaand a B.A. from St. John’s College.
Wendell Lim, Ph.D. – Dr. Lim is chair of the Department of Cellular and Molecular Pharmacologyand professor at the University of California, San Francisco(UCSF). Dr. Lim also holds the Byers Distinguished Professorship at UCSF. As an investigator at the Howard Hughes Medical Institute, Dr. Lim’s laboratory is conducting research on the logic of cell signaling systems. Dr. Lim has served on the Board of Scientific Counselors for the National Cancer Institutesince 2006 and is Deputy Director of the National Science Foundation Synthetic Biology Engineering Research Center. Dr. Lim is also Director of the University of California San Francisco(UCSF)/ University of California Berkeley National Institutesof Health (NIH) Nanomedicine Development Centerand of the UCSF Center for Systems & Synthetic Biology. Dr. Lim holds a Ph.D. and M.A. from the Massachusetts Institute of Technologyand an M.A., A.B.from Harvard University. He completed a postdoctoral training at Yale University.
The new advisors will join the existing SAB members, Chairman Ton Schumacher, Ph.D.,
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to advance allogeneic CAR T therapies for cancer and leverage the next generation of gene engineering and cell manufacturing technologies to advance therapies in solid tumors and other hematologic malignancies, and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the
Allogene Media/Investor Contact:
Chief Communications Officer
Source: Allogene Therapeutics, Inc.